Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients

Otokubo, Mai; Wada, Keita; Ikura, Megumi; Hayase, Kotoka; Uno, Takaya; Nakagita, Kazuki; Hayakawa, Naoki; Watanabe, Takuya; Seguchi, Osamu; Fukushima, Norihide; Nakamura, Tsutomu

doi:10.1248/bpb.b21-00860

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 Kidney transplant recipients with a polymorphism in ABCC4, a multidrug efflux transporter, have been shown to be at risk of a decline in neutrophil count during valganciclovir treatment. 44 Valganciclovir has been associated with neutropenia in 40%-77.3% of solid organ transplant recipients, 45,46 with several studies associating neutropenia with valganciclovir 'overexposure'. 47,48 Incidence of neutropenia 51 The degree of neutropenia in these settings is typically mild-to-moderate and will resolve within days to weeks, depending on the pathogen.…”

Section: Ta B L E 1 Classification Of Severity Of Neutropeniamentioning

confidence: 99%

Neutropenia in pediatric solid organ transplant

Harshman

Williams

Engen

2022

Pediatric Transplantation

View full text Add to dashboard Cite

Neutropenia is generally defined as an absolute neutrophil count in the circulation of less than 1500/mm3 and occurs in up to 25%–30% of pediatric solid organ transplant recipients (SOT) within the first year after transplantation. In the SOT population, neutropenia is most often a result of drug‐induced bone marrow suppression but can also be secondary to viral infection, nutritional deficiencies, lymphoproliferative infiltrate, and inherited causes. Outcomes for patients with neutropenia vary by degree of neutropenia and type of solid organ transplant. Management of neutropenia should begin by addressing the underlying cause, including reducing or removing medications when appropriate, treating infections, and addressing nutrient deficiencies; however, consultation with an experienced pediatric hematologist and use of granulocyte colony‐stimulating factor (G‐CSF) may be helpful in some cases. Overall, data on clinical outcomes for G‐CSF use remain limited, but observational studies may support its use in patients with infections or severe neutropenia.

show abstract